Open Access Articles- Top Results for Renzapride


Systematic (IUPAC) name
Clinical data
109872-41-5 7pxN
PubChem CID 3086547
IUPHAR ligand 244
ChemSpider 16736758 7pxY
UNII 9073C0W4E9 7pxY
ChEMBL CHEMBL289753 7pxN
Chemical data
Formula C16H22ClN3O2
323.818 g/mol
 14pxN (what is this?)  (verify)

Renzapride is a gastroprokinetic agent and antiemetic which acts as a full 5-HT4 full agonist and 5-HT3 antagonist.[1][2] It also functions as a 5-HT2B antagonist and has some affinity for the 5-HT2A and 5-HT2C receptors, though it is unlikely that these properties contribute to its therapeutic effects.[1]

Renzapride was being developed by Alizyme plc of the United Kingdom.

Clinical trials

Renzapride was being investigated for the treatment of constipation-predominant irritable bowel syndrome (IBS-C). It is also potentially effective for irritable bowel syndrome with alternating stool pattern (IBS-A). It is being developed by Alizyme plc of the United Kingdom.

As of 23 April 2008, Alizyme ceased all development of renzapride, after a Phase III trial in the U.S. did not show enough efficacy over placebo to justify further development.[3]


  1. ^ a b Meyers NL, Hickling RI. (2008). "Pharmacology and metabolism of renzapride : a novel therapeutic agent for the potential treatment of irritable bowel syndrome.". Drugs R D. 9 (1): 37–63. PMID 18095752. 
  2. ^ Camilleri M., McKinzie S., Fox J., Foxx-Orenstein A., Burton D., Thomforde G., Baxter K. and Zinsmeister A. R. (2004). "Effect of Renzapride on Transit in Constipation-Predominant Irritable Bowel Syndrome", Clin. Gastroent. and Hepatology; 2:895-904
  3. ^ "Results from Renzapride" (Press release). Alizyme plc. 23 April 2008. Retrieved 7 May 2009. 

Lua error in package.lua at line 80: module 'Module:Buffer' not found.